144 related articles for article (PubMed ID: 22952047)
1. The degree of tumor volume reduction during the early phase of induction chemotherapy is an independent prognostic factor in patients with high-risk neuroblastoma.
Yoo SY; Kim JS; Sung KW; Jeon TY; Choi JY; Moon SH; Son MH; Lee SH; Yoo KH; Koo HH
Cancer; 2013 Feb; 119(3):656-64. PubMed ID: 22952047
[TBL] [Abstract][Full Text] [Related]
2. Role of surgery in the treatment of patients with high-risk neuroblastoma who have a poor response to induction chemotherapy.
Du L; Liu L; Zhang C; Cai W; Wu Y; Wang J; Lv F
J Pediatr Surg; 2014 Apr; 49(4):528-33. PubMed ID: 24726106
[TBL] [Abstract][Full Text] [Related]
3. [Value of prognostic factors in the Austrian A-NB87 Neuroblastoma Study].
Ladenstein R; Ambros PF; Urban C; Ambros IM; Fink FM; Zoubek A; Grienberger H; Schmitt K; Kerbl R; Horcher E; Amann G; Höfler G; Heinzl H; Gadner H; Mutz I
Klin Padiatr; 1996; 208(4):210-20. PubMed ID: 8926686
[TBL] [Abstract][Full Text] [Related]
4. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
5. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma.
De Bernardi B; Nicolas B; Boni L; Indolfi P; Carli M; Cordero Di Montezemolo L; Donfrancesco A; Pession A; Provenzi M; di Cataldo A; Rizzo A; Tonini GP; Dallorso S; Conte M; Gambini C; Garaventa A; Bonetti F; Zanazzo A; D'Angelo P; Bruzzi P;
J Clin Oncol; 2003 Apr; 21(8):1592-601. PubMed ID: 12697885
[TBL] [Abstract][Full Text] [Related]
6. Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma.
Cai JY; Tang YJ; Jiang LM; Pan C; Chen J; Tang JY
Pediatr Blood Cancer; 2007 Dec; 49(7):952-7. PubMed ID: 17514736
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients.
Kim MS; Lee SY; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Jeon DG
Ann Surg Oncol; 2008 Mar; 15(3):906-14. PubMed ID: 18163171
[TBL] [Abstract][Full Text] [Related]
8. Tumor histology during induction therapy in patients with high-risk neuroblastoma.
George RE; Perez-Atayde AR; Yao X; London WB; Shamberger RC; Neuberg D; Diller L
Pediatr Blood Cancer; 2012 Sep; 59(3):506-10. PubMed ID: 22162143
[TBL] [Abstract][Full Text] [Related]
9. Neuroblastoma.
Meir HM; Balawi I; Nayel H; Yousef MK; Badawood S; Al-Mobarak M
Saudi Med J; 2001 Aug; 22(8):674-80. PubMed ID: 11573111
[TBL] [Abstract][Full Text] [Related]
10. [The prognostic significance of tumor volume in osteosarcoma with neoadjuvant chemotherapy].
Rehan N; Bieling P; Winkler P; Helmke K; Maas R; Baldini N; Heise U; Fuchs N; Winkler K
Klin Padiatr; 1993; 205(4):200-9. PubMed ID: 8377444
[TBL] [Abstract][Full Text] [Related]
11. [Can intensive induction chemotherapy eradicate retroperitoneal lymph node metastases in children over 1 year of age with stage 4 neuroblastoma?].
Niezgoda A; Balwierz W; Bysiek A; Miezyński W; Klekawka T; Garus K
Przegl Lek; 2004; 61 Suppl 2():9-13. PubMed ID: 15686039
[TBL] [Abstract][Full Text] [Related]
12. Needle core vs open biopsy for diagnosis of intermediate- and high-risk neuroblastoma in children.
Hassan SF; Mathur S; Magliaro TJ; Larimer EL; Ferrell LB; Vasudevan SA; Patterson DM; Louis CU; Russell HV; Nuchtern JG; Kim ES
J Pediatr Surg; 2012 Jun; 47(6):1261-6. PubMed ID: 22703803
[TBL] [Abstract][Full Text] [Related]
13. Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial.
Wagner LM; Billups CA; Furman WL; Rao BN; Santana VM
J Clin Oncol; 2004 May; 22(10):1886-93. PubMed ID: 15143081
[TBL] [Abstract][Full Text] [Related]
14. Neuroblastoma in Turkish children: experience of a single center.
Aydn GB; Kutluk MT; Yalçn B; Büyükpamukçu M; Kale G; Varan A; Akyüz C; Senocak ME; Büyükpamukçu N
J Pediatr Hematol Oncol; 2009 Jul; 31(7):471-80. PubMed ID: 19564739
[TBL] [Abstract][Full Text] [Related]
15. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma.
Kushner BH; Kramer K; LaQuaglia MP; Modak S; Yataghene K; Cheung NK
J Clin Oncol; 2004 Dec; 22(24):4888-92. PubMed ID: 15611504
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours.
Fosså SD; Stenning SP; Gerl A; Horwich A; Clark PI; Wilkinson PM; Jones WG; Williams MV; Oliver RT; Newlands ES; Mead GM; Cullen MH; Kaye SB; Rustin GJ; Cook PA
Br J Cancer; 1999 Jul; 80(9):1392-9. PubMed ID: 10424741
[TBL] [Abstract][Full Text] [Related]
17. Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma.
Shankar AG; Ashley S; Craft AW; Pinkerton CR
Med Pediatr Oncol; 2003 Mar; 40(3):141-7. PubMed ID: 12518341
[TBL] [Abstract][Full Text] [Related]
18. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution.
Hartmann O; Valteau-Couanet D; Vassal G; Lapierre V; Brugières L; Delgado R; Couanet D; Lumbroso J; Benhamou E
Bone Marrow Transplant; 1999 Apr; 23(8):789-95. PubMed ID: 10231141
[TBL] [Abstract][Full Text] [Related]
20. Disease control intervals in high-risk neuroblastoma.
Santana VM; Furman WL; McGregor LM; Billups CA
Cancer; 2008 Jun; 112(12):2796-801. PubMed ID: 18429000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
